Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others. Reference standards of Navitoclax API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.
stdClass Object ( [pname] => Navitoclax - API Standards [catalogue_number] => PA 14 82000 [category_ids] => ,69,81,78,70,82,88, [chemical_name] => [weight] => 974.61 [form] => C47H55ClF3N5O6S3 [cas] => 923564-51-6 [pslug] => 923564-51-6-navitoclax-api-pa1482000 [latest_product] => 0 [linkproducts] => 0 [offers_id] => [offers_name] => [offers_status] => [offers_start_date] => [offers_end_date] => [pageview] => [offers_slug] => [offers_product_id] => [offers_product_code] => [offers_master_id] => [offer_percentage] => [offers_product_main_cat] => )
Catalogue No.:PA 14 82000
CAS :
Molecular Formula : C47H55ClF3N5O6S3
Molecular Weight : 974.61
I accept terms and conditions
Message sent successfully!! We will get back to you shortly ....
